DOI: 10.12890/2021_002190

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)

Authors

  • Silvia Ciotti USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Antonella Cometa USL Umbria 2, Department of Rehabilitation, S.M. Stella, Orvieto, Italy
  • Claudia De Carlo USL Umbria 2, Department of Rehabilitation, Domus Gratiae, Terni, Italy
  • Giancarlo Martini Department of Rehabilitation, Ospedale di Cascia, Italy
  • Andrea Marona USL Umbria 2, Department of Neuroradiology, Ospedale S.G. Battista di Foligno, Italy
  • Laura Filippetti USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Diego Carducci USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista di Foligno, Italy
  • Silvano Baratta USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Mauro Zampolini USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista di Foligno, Italy
  • Francesco Corea USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista di Foligno, Italy

francesco.corea@uslumbria2.it

Keywords

Multiple sclerosis, neurofibromatosis 1, neurorehabilitation, natalizumab, case report

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease which confers an increased risk of malignant tumour development. Relapsing remitting multiple sclerosis (RRMS) is an inflammatory demyelinating disease of the central nervous system. The coexistence of multiple sclerosis and NF1 is rare but has been reported. Here, we describe the case of a 31-year-old man with NF1 and subacute walking problems with proximal pain in the lower limbs who was successfully treated with natalizumab.

View the entire article

Downloads

References

  1. Bergqvist C, Hemery F, Ferkal S, Wolkenstein P. Neurofibromatosis I and multiple sclerosis. Orphanet J Rare Dis 2020;15(1):186.
  2. Perini P, Gallo P. The range of multiple sclerosis associated with neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 2001;71(5):679–681.
  3. Iwanowski P, Kowalska M, Prendecki M, Dorszewska J, Kozubski W, Rydzanicz M, et al. Primary progressive multiple sclerosis and neurofibromatosis type 1. Mult Scler Relat Disord 2019;32:66–69.
  4. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162–173.
  5. Etemadifar M, Fatehi F, Sahraian MA, Borhanihaghighi A, Ardestani PM, Kaji-Esfahani M, et al. Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran. Mult Scler 2009;15(9):1126–1130.
  6. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, et al. Italian iMed-Web database. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015;138(Pt 11):3275–3286.

Published

2021-02-03

Issue

Vol. 8 No. 2 (2021)

How to Cite

1.
Ciotti S, Cometa A, De Carlo C, Martini G, Marona A, Filippetti L, et al. Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS) . EJCRIM [Internet]. 2021 Feb. 3 [cited 2026 Nov. 3];8(2). Available from: https://ejcrim.com/index.php/ejcrim/article/view/2190

Most read articles by the same author(s)